Nuvalent Inc. (NASDAQ:NUVL) is one of the best high short interest stocks with huge upside potential. On June 24, Nuvalent ...

Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

New data indicate a targeted drug from Nuvalent could help patients with a rare lung cancer for whom other drugs stopped ...

Brain metastases are common in ROS1-positive NSCLC, particularly after disease progression. Among 56% with measurable brain lesions, zidesamtinib mounted a 48% intracranial ORR, including 20% ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced positive ...

New study results position Nuvalent to bring forward what it claims is a differentiated treatment for ROS1-positive lung ...

Nuvalent's promising trial results for zidesamtinib show a 44%-51% response rate in ROS1-positive lung cancer. Read more here ...

ROS1-positive NSCLC is a rare, aggressive form of lung cancer harboring rearrangements in the ROS1 gene. 7 These mutations are present in just 1% to 2% of all cases of NSCLC. An oncogene, ROS1 can ...

Cambridge, Massachusetts-based Nuvalent has reported the results of its phase 1/2 ARROS-1 trial of zidesamtinib in previously ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the ...